- Home
- CISO vs BOLD Comparison
CISO vs BOLD Comparison
Compare CISO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CISO | BOLD |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 26.2M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | CISO | BOLD |
|---|---|---|
| Price | $0.46 | $1.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 817.2K | 185.6K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,743,266.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $1.00 |
| 52 Week High | $3.84 | $3.45 |
Technical Indicators
Market Signals| Indicator | CISO | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 30.24 | 46.46 |
| Support Level | $0.46 | $1.11 |
| Resistance Level | $0.60 | $1.20 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 3.33 | 75.00 |
Price Performance
Historical ComparisonAbout CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.